Cetera Advisors’s Nektar Therapeutics NKTR Stock Holding History

Cetera Advisors’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	$11.2K	Sell	800 -20	-2%	-$209	﹤0.01%	2411
2023 Q4	$6.95K	Sell	820 -27	-3%	-$204	﹤0.01%	1781
2023 Q3	$7.56K	Sell	847 -305	-26%	-$2.94K	﹤0.01%	1692
2023 Q2	$9.94K	Sell	1,152 -5	-0.4%	-$53	﹤0.01%	1646
2023 Q1	$12.2K	Sell	1,157 -40	-3%	-$1.21K	﹤0.01%	1634
2022 Q4	$40.6K	Sell	1,197 -20	-2%	-$968	﹤0.01%	1552
2022 Q3	$58K	Hold	1,217	–	–	﹤0.01%	1235
2022 Q2	$69K	Hold	1,217	–	–	﹤0.01%	1318
2022 Q1	$98K	Buy	1,217 +208	+21%	+$30.8K	﹤0.01%	1358
2021 Q4	$204K	Buy	+1,009	New	+$219K	﹤0.01%	1319

Other funds holding NKTR

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Cetera Advisors's NKTR Position: Q1 2024 in Review

Cetera Advisors reduced its Nektar Therapeutics (NKTR) stake by 2.4% in Q1 2024, selling an estimated $209 and leaving 800 shares worth $11.2K. The position accounts for ﹤0.01% of the portfolio, ranked #2411.

Cetera Advisors first reported a position in NKTR in Q4 2021 and has held it in 10 quarters since. The position peaked at $204K in Q4 2021. 124 funds tracked by Wall St. Rank hold NKTR as of Q1 2024.

Cetera Advisors held 800 shares of Nektar Therapeutics worth $11.2K as of Q1 2024.
Cetera Advisors sold 20 Nektar Therapeutics shares in Q1 2024, an estimated $209.
Nektar Therapeutics made up ﹤0.01% of Cetera Advisors's portfolio in Q1 2024, its #2411 holding.
Cetera Advisors first reported a position in Nektar Therapeutics in Q4 2021 and has held it in 10 quarters since.
Cetera Advisors's Nektar Therapeutics position peaked at $204K in Q4 2021.
124 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2024.

Based on Cetera Advisors's 13F filing for Q1 2024, filed 15 May 2024.